Chris Takimoto

Chris Takimoto

Director/Board Member at ALX ONCOLOGY HOLDINGS INC.

Net worth: - $ as of 30/05/2026

67 year
Health Technology
Consumer Services

Profile

Chris H.
Takimoto
is currently an Independent Director at ALX Oncology Holdings, Inc. since 2025 and Global Chief Medical Officer at The Start Center For Cancer Research.
Former roles include Chief Medical Officer at IGM Biosciences, Inc. from 2021 to 2024, Senior Vice President-Oncology at Gilead Sciences, Inc. from 2020 to 2021, Chief Medical Officer at Forty Seven LLC from 2016 to 2020, VP-Experimental Medicine Early Development at Janssen Global Services LLC from 2010 to 2016, Senior Director-Translational Medicine at Ortho Biotech Oncology Research & Development from 2008 to 2010, and Associate Professor at the University of Texas Health Science Center At San Antonio.
Education includes undergraduate studies at Stanford University and doctorate degrees from Yale University and Yale School of Medicine.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
30/03/2026 0 ( -.--% ) - $ 30/05/2026

Chris Takimoto active positions

CompaniesPositionStart
ALX ONCOLOGY HOLDINGS INC. Director/Board Member 20/01/2025

Former positions of Chris Takimoto

CompaniesPositionEnd
IGM BIOSCIENCES, INC. Chief Tech/Sci/R&D Officer 30/09/2024
GILEAD SCIENCES, INC. Corporate Officer/Principal 30/06/2021
FORTY SEVEN, INC. Chief Tech/Sci/R&D Officer 31/03/2020
Corporate Officer/Principal 31/12/2015
Ortho Biotech Oncology Research & Development
Corporate Officer/Principal 31/12/2009
See the detail of Chris Takimoto's experience

Training of Chris Takimoto

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

13

1st degree connections

10

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies10

Health Technology

Consumer Services

Consumer Services

Health Technology

Health Technology

Consumer Services

Health Technology

Ortho Biotech Oncology Research & Development

Consumer Services

Health Technology

  1. Stock Market
  2. Insiders
  3. Chris Takimoto